Fady T Botros

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 5

Top Topics

Epidermal Growth Factor Receptor

Cardiovascular Disease

Top Venues

Diabetes, obesity & metabolism

This page only lists publications with an associated author ORCID identifier.

Publications

Richard M Bergenstal, Athena Philis-Tsimikas, Carol H Wysham, Molly C Carr, Juliana M Bue-Valleskey, Fady T Botros, Thomas Blevins, Julio Rosenstock
Once-weekly insulin efsitora alfa: Design and rationale for the QWINT phase 3 clinical development programme. Diabetes, obesity & metabolism 26 (8) (2024)
Richard M Bergenstal, Athena Philis-Tsimikas, Carol H Wysham, Molly C Carr, Juliana M Bue-Valleskey, Fady T Botros, Thomas Blevins, Julio Rosenstock
Once-weekly insulin efsitora alfa: Design and rationale for the QWINT phase 3 clinical development programme. Diabetes, obesity & metabolism (2024)
Fady T Botros, Ulagamadesan Venkatesan, Raleigh Malik, Claudia Nicolay, Anastasia Hoover, Ibrahim Turfanda, Helen Martina Colhoun, Jonathan E Shaw
Dulaglutide and Kidney Function-Related Outcomes in Type 2 Diabetes: A REWIND Post Hoc Analysis. Diabetes care (2023)
Edward Franek, Ulagamadesan Venkatesan, Matthew C Riddle, Claudia Nicolay, Ana Hickey, Fady T Botros, Li Shen Loo
Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trial. Diabetes, obesity & metabolism 24 (9) (2022)
Katherine R Tuttle, Mark C Lakshmanan, Brian Rayner, Alan G Zimmermann, Brad Woodward, Fady T Botros
Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7). Diabetes, obesity & metabolism 21 (6) (2019)